Table 2.
Provocation of Arrhythmogenic Triggers from PLSVC.
| Group A (n = 14) | Group B (n = 23) | ||
|---|---|---|---|
| Arrhythmogenic Triggers (+) |
Arrhythmogenic Triggers (−) |
p-Value | |
| Age (years) | 53 ± 8.8 | 72 ± 5.9 | <0.001 |
| Male, n (%) | 10 (71%) | 15 (62%) | 0.98 |
| LA diameter (mm) | 34.3 ± 5.1 | 40.7 ± 4.8 | 0.0011 |
| Paroxysmal AF | 12 (86%) | 18 (78%) | 0.89 |
| AF duration (months) | 33 ± 22 | 26 ± 20 | 0.35 |
| Left ventricular ejection fraction (%) | 62.6 ± 9.1 | 61.5 ± 9.2 | 0.79 |
| Diameter of the PLSVC (mm) | 19.1 ± 8.5 | 20.5 ± 6.3 | 0.50 |
| Antiarrhythmic drugs, n (%) | 2, (14%) | 4, (17%) | 0.83 |
| Amiodarone, n (%) | 0, (0%) | 0, (0%) | - |
| CHADS2-VASc | 0.77 ± 1.01 | 3.11 ± 1.49 | <0.001 |
| Redo RFCA | 4 (28%) | 4 (17%) | 0.71 |
| TIA/Stroke within 30 days | 0 (0%) | 0 (0%) | - |
| Cardiac tamponade | 0 (0%) | 0 (0%) | - |
| Procedure time (m) | 186 ± 58 | 137 ± 38 | <0.001 |
LA, left atrium; AF, atrial fibrillation; PLSVC, persistent left superior vena cava; RFCA, radiofrequency catheter ablation; TIA, transient ischemic attack.